hopes that triple ACT will keep malaria deaths from rising-at least until a fundamentally different and novel type of antimalarial drug is ready for use. The three front-runners in the pipeline-OZ439 from Sanofi, KAE609 from Novartis and DSM265 from the US National Institutes of Health and Takeda Pharmaceuticals-might be used in combination either with each other or with some of the existing treatments. Depending on the speed of the drug-approval process, a combination therapy based on at least one of these key components could enter circulation as early as 2020. But White fears that conventional ACT may fail before then in certain regions, which is why he calls the current TRAC trial vital.
When TRAC formed, ACT was still effective, despite the emergence of artemisinin resistance. Although a small fraction of P. falciparum strains had naturally acquired mutations that made them less vulnerable to artemisinin, any such parasites that managed to escape that component of ACT were wiped out by the partner drug. This is the driving concept behind combination therapies: if a pathogen develops mutations that enable it to resist one drug, the second drug will kill it. But this means that the partner drug must combat more parasites on its own-and that increases the chance that a tiny fraction of them will contain natural mutations that allow them to overcome the partner drug as well. "The 220 VOLUME 22 | NUMBER 3 | MARCH 2016 NATURE MEDICINE On 7 January, a study confirmed what a few scientists had long suspected: the prevalence of multidrug-resistant malaria has grown. Researchers found that nearly 40% of people with malaria in Pursat, a province at the foothills of the Cardamom Mountains in western Cambodia, could not be cured by a gold-standard treatment known as artemisininbased combination therapy (ACT) 1 . The therapy consists of a course of pills that are taken over three consecutive days, and it cures malaria within a week. The pills include artemisinin, a sweet wormwood extract whose discoverer won a Nobel Prize last year, in combination with one of several longer-lasting partner drugs. Resistance to artemisinin, the key ingredient in ACT, had already been observed in regions of Cambodia, Thailand, Myanmar, Vietnam, Laos and along the Indian border. Yet until this recent study, reports of ACT failure were exceedingly rare. Nick White, a malaria specialist at Mahidol University in Thailand, stresses the urgency of the situation. "So much effort and money has gone into eliminating malaria in the past few decades, and here is something that could really sink all of that, " he says. He and other researchers fear that ACT failure could become more widespread. This is the nightmare scenario that malaria experts have fretted about since ACT became the WHO-recommended gold standard in 2001. In general, pathogens naturally acquire mutations that protect them against drugs, so it was only a matter of time before Plasmodium falciparum, the parasite responsible for the malaria deaths worldwide, did just that. In 2006, news of resistance to artemisinin surfaced, and as the situation grew more dire, in 2011, an international team of researchers formed the Tracking Resistance to Artemisinin Collaboration, known as TRAC. The group includes scientists from Mahidol University in Thailand, the University of Oxford, UK, and the Medical Research Council' s Center for Genomics and Global Health also in Oxford, among others. The group's first study, completed in 2013, mapped the spread of artemisinin resistance in Southeast Asia 2 . In November last year, members of the team began to enroll participants in the second TRAC study, a clinical trial called TRAC II. Their chief goal is to find a therapy that can treat people who have multidrug-resistant malaria and no longer respond to ACT.
The treatment tested in TRAC II consists of three parts, rather than the two-part combination used in conventional ACT. It is the first time that a triple treatment involving artemisinin has been systematically tested to treat malaria. In addition to artemisinin, 'triple ACT' includes the partner drug piperaquine, along with another old, longlasting malaria drug called mefloquine.
White, an investigator on the TRAC II trial, WHO in May 2015 seek to maintain the efficacy of partner drugs in ACT, because it seems as if partial artemisinin resistance might be inevitable. If triple ACT or the synthetic combination cures more people in western Cambodia than does the faltering, first-line ACT, the medicines might see a relatively quick rollout because of the urgency of the situation. Indeed, treating people who are extensively drug-resistant is one goal of the study. It is less clear, however, how these experimental combinations would be deployed in regions of the world where ACT still works. "We're just looking for the triple combination to not be inferior to current ACTs, " White says. Even if the new drugs are safe and effective, reports of mild side effects such as temporary fatigue, or the inconvenience of taking additional pills until manufacturers manage to package all three drugs into a single pill, may persuade policymakers to stick with the ACTs that are already in circulation because there is a substantial cost involved in such a change. Still, White says that the obstacles associated with triple ACT can be overcome. "We use multiple drugs to fight cancer, tuberculosis and HIV because of the same principles of drug resistance, " he says, "so I don't see why malaria should be any different. " Amy Maxmen is a freelance science journalist based in Berkeley, California.
sequence we see is that artemisinin resistance appears, then partner-drug resistance, and that is followed by a failure of the ACT, " says Arjen Dondorp, a tropical medicine specialist at the University of Oxford and a lead investigator on the TRAC II trial. In Pursat, artemisinin is usually paired with piperaquine in ACT. But now, a decade since artemisinin resistance was first recognized in the region, so many malarial parasites have acquired resistance to piperaquine that the conventional ACT failed in more than a third of the people in the recent study-putting them at risk of death. Whereas the incidence of malaria has decreased on average around the world, falling from an estimated 262 million cases in 2000 to 214 million in 2015 (ref.
3), the Regional Artemisinin Initiative in Southeast Asia reports that the number of malaria cases rose in Cambodia last year, and that "the malaria situation in Cambodia looks set to deteriorate further in the coming months 4 . " However, researchers do not know whether the resurgence is due to resistance or to other issues, such as a lack of available treatments.
Treatment trio
In January 2014, researchers pinpointed the gene that underlies artemisinin resistance, named kelch13 5 . Normally, artemisinin kills most P. falciparum within two days, but parasites that resist the drug live longer than three days. The following July, the results of the first TRAC study were published. By sequencing the kelch13 gene from specimens of P. falciparum collected from individuals with malaria across Southeast Asia and Africa, the investigators found mutations in the gene were prevalent across Southeast Asia 2 . Although the gene's mechanistic role is not fully understood, at least one study in 2015 found that the presence of a mutation in kelch13 led to an elevation in the levels of phosphatidylinositol 3-phosphate (PI3P), a phospholipid that aids in protein trafficking in the cell 6 . The elevated levels induced artemisinin resistance, the study suggested.
Investigators in the TRAC II trial hope that the combination of artemisinin with piperaquine and mefloquine will be infallible. This is because, for reasons that are not fully understood, P. falciparum seems unable to simultaneously mount resistance to both piperaquine and mefloquine, says Pascal Ringwald, coordinator of the WHO' s malaria drug efficacy and response unit. "The concept of triple combination is based partly on the discovery that some types of resistance are mutually exclusive, " says Ringwald, who is not involved in the trial, "and I think that is a genius idea. " TRAC II will cover 17 sites in eight countries (16 in Asia and one in sub-Saharan Africa) and end in 2017. In addition to comparing the efficacy of two-drug ACT to that of triple ACT, the trial will test ACTs that include synthetic artemisinin-a formulation of the antimalarial substance arterolane-in combination with piperaquine. Given that the molecular structure of arterolane differs from that of natural artemisinin, and that the synthetic drug seems to bind to a different spot on the malaria parasite than does natural artemisinin, the team hopes that kelch13 mutations will not enable malaria parasites to resist the synthetic version.
In March 2015, researchers found that kelch13 mutations arose separately in various regions, as opposed to spreading across country borders 7 . On the basis of these new details, policymakers in Southeast Asia and at the WHO have revised malaria control strategies. Whereas initiatives proposed by malaria experts in 2011 sought to contain artemisinin resistance through radical measures at the Cambodia and Myanmar borders-such as using ACT as a prophylaxis by treating everyone with the pills, regardless of a diagnosis-new strategies announced by the 
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